Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Current Deferred Revenue: 2022-2024

Historic Current Deferred Revenue for Orchestra BioMed Holdings (OBIO) over the last 3 years, with Dec 2024 value amounting to $4.4 million.

  • Orchestra BioMed Holdings' Current Deferred Revenue rose 14.34% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 million, marking a year-over-year increase of 14.34%. This contributed to the annual value of $4.4 million for FY2024, which is 76.85% up from last year.
  • Orchestra BioMed Holdings' Current Deferred Revenue amounted to $4.4 million in FY2024, which was up 76.85% from $2.5 million recorded in FY2023.
  • In the past 5 years, Orchestra BioMed Holdings' Current Deferred Revenue registered a high of $6.4 million during FY2022, and its lowest value of $2.5 million during FY2023.
  • In the last 3 years, Orchestra BioMed Holdings' Current Deferred Revenue had a median value of $4.4 million in 2024 and averaged $4.5 million.
  • Per our database at Business Quant, Orchestra BioMed Holdings' Current Deferred Revenue slumped by 61.00% in 2023 and then soared by 76.85% in 2024.
  • Orchestra BioMed Holdings' Current Deferred Revenue (Yearly) stood at $6.4 million in 2022, then slumped by 61.00% to $2.5 million in 2023, then soared by 76.85% to $4.4 million in 2024.